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Abstract
Objective: Orthotopic models are important in cancer research. Here we developed orthotopic xenograft mouse 
model of metastatic lung cancer and glioblastoma with a specially designed system.
Methods: Tiny fragments of surgical tumors were implanted into the mice brain with a trocar system. 
Immunohistochemistry was performed to detect brain tumor stem cells among glioblastoma tissues, including both 
the original and resulting ones with monoclonal antibody against CD133.
Results: Besides the constant high take rates in both models; brain transplants perfectly resembled their original 
tumors in biological behaviors. The brain tumor stem cells, positively stained with CD133 were found, though not 
frequently, in both original and resulting glioblastoma tissues.
Conclusions: Orthotopic model established with a trocar system is effective and injection of tumor tissues containing 
stem cells promise the forming of new tumor mass when grafted.
Background
Animal models have been extremely critical in the under-
standing of cancer and in the pre-clinical testing of new
antitumor drugs since 1960s when it was first developed
by implanting human colon carcinoma to nude mice [1].
The utility of each particular model, nevertheless,
depends on how close it replicates the original tumor. To
the present days, several kinds of animals, like dog, mon-
key, and murine, have ever been tested and compared
between each other for the purpose of finding the best
host for transplantation [2-4]. The results indicated that
though the extent to which murine models recapitulate
the features encountered in human tumor is still contro-
versial, considering their reproducibility and availability,
they still constitute a valuable in vivo system for the pre-
clinical studies.
Not surprisingly, an orthotopic model is much more
superior to a heterotransplantation model in that the for-
mer recapitulates the original tumor more likely. As far as
human brain tumors are concerned, the orthotopic mod-
els currently available are established either by stereo-
taxic injection of cell suspensions [5-8] or implantation in
solid piece through complicated craniotomy [9,10]. Tak-
ing into consideration both the advantages and disadvan-
tages of the current methods, there is still much room for
improvement. Recently, high success rate of model devel-
opment of brain tumor were established using cell sus-
pensions directly derived from fresh patient brain tumors
indicating the important role of stromal cells in tumor
formation [11].
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In the current study, we developed orthotopic xeno-
graft mouse model by injecting tiny tumor tissue, but not
cell suspensions, into the brain of mouse with a special
trocar system. It is argued that the organ-specific
microenvironment plays a determining role in the growth
patterns of transplanted tumors [12,13]. To observe the
growth patterns of different tumor types implanted to the
same organs, we chose primary glioblastoma multiforme
and brain metastasis for transplantation in this study. The
growth of xenografts in the mice brain was observed with
MRI. Histological study was also performed to explore
and compare the growth features of these two biologically
distinctive malignances. With the identification of CD133
positive cells from brain tumor tissues, more and more
reliable evidences support the assumption that CD133+
cell is the tumor initiating cells or cancer stem cells[14-
16]. In this study, we also examined the distribution of




Our study was approved by the Medical Review Board of
Soochow University Medical School. The donor tissues
obtained at surgery after written consent consisted of
typical glioblastoma multiforme (WHO classification
2000) and brain metastasis from lung adenocarcinoma.
Tumor tissue was dissected free of blood clot, washed,
and minced into 0.5-mm-thick slices for grafting.
Reagents and equipments
Alcian blue/PAS dyeing reagent was provided by pathol-
ogy department of our hospital; Rabbit anti-carcinoem-
bryonic antigen (CEA) monoclonal antibody, horseradish
peroxidase(HRP), and 3,3'-Diaminobenzidine(DAB) were
offered by pathology department of Changhai hospital,
affiliated hospital of the second military medical univer-
sity; EGFR((BDbioscience Co.); CD133((Miltenyi Biotec);
24# trochar(B. Braun Melsungen AG); Micro-drill 18000-
17(Fine Science Tools); Supraconduction nuclear mag-
netic resonance formatter equipped with micro-23 wind-
ings(Philips Achieva).
Animals
Four to six-week-old male and female NC nude mice at
an average weight of 25 g were purchased from the Cen-
ter for Experimental Animals, Soochow University (cer-
tificate No. SY X K (Su) 2007-0035). All the animals were
bred and maintained in the Specific Pathogen Free Ani-
mal Care Facility, Nasal1000 grade. The National Insti-
tutes of Health guidelines for the care and use of
laboratory animals were followed in all animal proce-
dures.
Orthtotopic tumor tissue transplantation and further 
propagation
For transplantation, we designed a very simple but ingen-
uous injection system. This system includes a 24# trocar
and a specifically made propeller. The propeller matches
well with the rear part of the trocar and is used to pack
the tumor tissue in the trocar cannula. When the trocar
filled with tumor tissue is navigated by stereotaxic instru-
ment to the injection destination, trocar needle was
introduced to slowly and smoothly push tumor tissue out.
The injected volume could be strictly controlled accord-
ing to the length on the cannula which is quantitated by 2
mm3 water (Figure 1). In this study, all the surgical proce-
dures were carried out under general anesthesia by intra-
peritoneal injection of 10% chloral hydrate (200 mg/kg).
A small burr hole, 2 mm in diameter was made 2 mm to
the midline and 0.5 mm anterior to bregma using micro-
skull drill. Trochar packed with donor tissue was navi-
gated to a depth of 3.5 mm via skull hole. Tumor tissue, 2
mm3 per mouse, was slowly and smoothly injected into
the caudate/putamen nuclei of the mouse brain. Skull
hole was sealed with bone wax and scalp sutured. The
implanted tumors in the mouse brain were passed from
animal to animal following the same procedure described
above for six generations in the metastasis group (15 mice
for the first generation and 10 mice for the other genera-
tions) and thirteen generations in glioblastoma multi-
forme group (10 mice per generation). Take rate of each
model and survival time of each mice were counted. As
mice usually died in 2 days after cachexia occurs, survival
time of tumor-bearing mice was calculated as 1 day +
days from transplantation to sacrifice.
Magnetic resonance imaging (MRI) of nude mice implanted 
with tumor tissues
After anesthetized as the same way described above, mice
were fixed in micro-23 winding mice MRI equipment. A
1.5 T clinical Signa version 5.5.1. (General Electric MS)
was used for brain imaging. Five apparently normal mice
were examined on day 10, 15, 20, 25 and day 30 post
tumor implantation to detect the growth of the grafted
tumor fragments. In enhanced scanning, 0.5 ml diethyl-
ene triaminepentaacetic acid gadolinium (Gd-DTPA 0.25
mmol/L) was intraperitoneally injected 10 minutes before
examination. Scanning parameters was as follows:
MATRIX 224X224; layer thickness: 3.0 mm; space
between layers: 0.3 mm T1WI: TR260ms and TE24ms.
Histological examination
Four mice that received orthotopic implantation of
human glioblastoma multiforme were sacrificed on day 5,
10, 15, or 20 to study brain tumor take. The other mice
were sacrificed when they became cachectic or at variousFei et al. Journal of Experimental & Clinical Cancer Research 2010, 29:84
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post-implantation times for morphological studies. The
overview of tumor mass and its relationship with adjacent
host brain structures was observed with a naked eyes or
low power lens. The brain tissues harboring xenografts
were fixed in 4% phosphate-buffered paraformaldehyde
for 18 hours, embedded in paraffin. Sections of all paraf-
fin-embedded blocks were stained with hematoxylin-
e o s i n  ( H E )  a n d  w i t h  A l c i a n  b l u e / P A S .  A s  C E A  i s  t h e
potent marker for lung adenocarcinoma and EGFR is spe-
cially expressed in glioblastoma multiforme, we also per-
formed immunohistochemistrical staining to examine
the expression of CEA and EGFR in xenografts derived
from metastatic adenocarcinoma or glioblastoma multi-
forme.
The CD133 expression in the original human glioblastoma 
and its transplants
CD133+ tumor cells are rare among tumor tissues, but
regarded as the initiating cells in the brain tumor forma-
tion. In this study, the glioblastoma tissues used for and
resulted from orthotopic implantation were obtained
processed and immunostained for CD133 expression as
described by Christensen et al [17].
Results
Efficient transplantation and high take rates were achieved
Due to the improvement of procedure, it took only about
5 minutes to finish the implantation (from anesthesia to
closure of skull hole) in one mouse. Moreover, no postop-
erative death happened. None of the mice with xenograft
developed focal neurological signs in the early and inter-
mediate periods, however, at the end of observation, all
the tumor-bearing mice presented with reduced food
intake, dull response, emaciated figure, skin fold and
cachexia. The take rates in brain metastasis group
increased gradually, with 33% for first generation, 50% for
the second generation, 70% for the third generation, and
100% from the 4th generation (table 1). In glioblastoma
group, the results were even more encouraging with suc-
cess rates of 90% for the first and second generations.
From 3rd generation, the tumorigenicity rate was steadily
up to 100% (table 2). Survival time of mice with metasta-
sis grafts varied considerably from mouse to mouse of the
first three generations, but tended to be similar from the
4th generation (38.0 ± 0.9 days n = 10, see table 1). Mice
in the glioblastoma group demonstrated the same ten-
dency, having a survival time of 23.9 ± 1.7 days (see table
2) from the 5th generation (n = 10).
Implanted tumors could be revealed by MRI
MRI scanning revealed tumor mass as early as day 20 for
metastasis group, and day 15 for glioblastioma multi-
forme. The imaging features of xenograts from brain
metastasis were apparently different from those of xeno-
grafts from gliomblastoma multiforme. The former has a
distinct boundary with adjacent normal parenchyma,
while glioblastoma multiforme was featured by vague
border and finger-like edema (Figure 2). Post-Gd-DTPA
sagittal T1W sequences revealed a typical enhancement
in both malignances.
Figure 1 Illustration of nude mice orthotopic transplantation with glioma tissue. A: micro-skull drill; B: trochar; C tissue propeller; inset in D and 
E: the depth of injection into mouse brain; G comminuted tumor tissue; H put some tissue into the rear part of trochar (see arrow); I: tumor tissues was 
packed to the trochar cannula with propeller for transplantation, superfluous tumor tissue were overflowed from the distal end of trochar under the 
pressure of propeller (see arrow);F and inset in J: exactly 2 mm3 tumor tissue lefted for transplantation (see black arrow); K: drill the hole; L:the burr hole; 
M: the tumor tissue (J) was injected slowly into brain via the hole (I), then pulled out the trochar slowly, sealed the hole with bone wax and sutured 
the scalp.Fei et al. Journal of Experimental & Clinical Cancer Research 2010, 29:84
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Gross morphology
Xenografts derived from brain metastasis were gray, soft
and featured by sharp boundary with adjacent normal
parenchyma. In glioblastoma models, tumors were gray
or yellowish, measuring from 6 to 8 mm in largest diame-
ter. Besides invasion to ipsilateral hemisphere, contralat-
eral spread was also observed though it was not frequent.
Extension of tumor mass to the skull and scalp soft tissue
was not found (Figure 3).
Histopathologic examination of implanted tumors
In HE sections, features common to xenografts of brain
metastasis included: a) sharp boundary between tumor
mass and surrounding normal brain tissue (Figure 4A and
4B); b) round and densely arranged tumor cells; c) abun-
dant caryocinesia; d) abundant acid mucus secretion by
tumor cells that were dyed blue by Alcian blue and red by
PAS; e) positive immunostaining for CEA (Figure 5A and
5B). Obviously, the transplantation of brain metastasis
tissues into the nude mice brain produced tumor mass
which perfectly recapitulated the original tumor type. In
contrast to the xenografts derived from brain metastasis,
the resulting tumors from human gliomblastomas dem-
onstrated variable cytoplasmic and nuclear pleomor-
phism on the preparations. Cellular forms ranged from
fusifirm, starlike to triangle with scant cytoplasm and
densely hyperchromatic nuclei. Bizarre, multinucleated
giant cells were frequently observed. Exuberant endothe-
lial proliferation in combination with necrosis was signif-
Table 1: Take rates in brain metastasis group and survival time of tumor-bearing mice.
Generation No. of mice No. of tumor-bearing 
mice1
Take rate(%) survival time(d)
1 15 5 33 47.6 ± 1.8
2 10 5 50 42.2 ± 1.8
3 10 7 70 40.8 ± 1.2
4 10 10 100 38.0 ± 0.9
5 10 10 100 38.6 ± 1.0
6 10 10 100 37.8 ± 0.9
1Each mouse was implanted with one graft (Site: right caudate nucleus of nude mice)
Take rates in brain metastasis group from lung adenocarcinoma and survival time of tumor-bearing mice in the intracranial 
xenotransplantation
Table 2: Take rates in glioblastoma group and survival time of tumor-bearing mice.
Generation No. of mice No. of tumor-bearing 
mice1
Take rate(%) survival time(d)
1 10 9 90 32.4 ± 2.1
2 10 9 90 30.4 ± 2.2
3 10 10 100 29.9 ± 2.1
4 10 10 100 28.4 ± 2.7
5 10 10 100 23.9 ± 1.7
6 10 10 100 23.0 ± 0.9
7 10 10 100 22.8 ± 1.3
8 10 10 100 21.7 ± 1.3
9 10 10 100 23.2 ± 0.6
10 10 10 100 22.0 ± 1.8
11 10 10 100 21.3 ± 1.2
12 10 10 100 21.4 ± 1.8
13 10 10 100 22.4 ± 0.9
1Each mouse was implanted with one graft(Site: right caudate nucleus of nude mice)
Take rates in glioblastoma group and survival time of tumor-bearing mice in the intracranial xenotransplantationFei et al. Journal of Experimental & Clinical Cancer Research 2010, 29:84
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icant (Figure 4C and 4D). EGFR, one of the important
markers for glioblastioma multiforme, was strongly
expressed on membrane and in cytoplasm of tumor cells
(Figure 5C).
CD133 + cells were seen in both the original tumors and the 
implanted tumors
Immunohistochemical staining for CD133 protein was
performed in sections made from the original glioblas-
toma multiforme and its successive xenografts. As a
result, CD133 positive cells were rare but observed in
each tumor tissue. It is rather intriguing that CD133 posi-
tive cells were prone to distribute at the border between
main tumor mass and the adjacent normal brain paren-
chyma (Figure 6).
Discussion
In the previous published orthotopic animal models of
brain malignances, the tumors were transplanted by cell
suspension injection [5-8] or surgical implantation via
craniotomy [9,10]. Cell suspension injection has once
been widely adopted due to the distinctive advantage of
micro-invasion. However, to acquire single cell suspen-
sions, trypsin is usually added to dissociated tumor tis-
sues or adherent cell lines, which inevitably reduced the
viability of the tumor cells. Secondly, because of the small
cranial cavity of mouse, the total volume of injected cell
suspension is limited to or less than 20 μl [5-8], which
means the relatively small number of could-be implanted
tumor cells. Furthermore, cell suspensions are deprived
of stromal component which is actually critical in the
tumor growth. Based on these listed reasons, it is not sur-
prising that implantation of tumor cell suspension
resulted in an overall take rate of less than 70% despite
the recent refinery in transplantation procedure. Partly
because the injection pressure or speed couldn't be well
controlled, the tumor cell suspension may flow into the
ventricle, and/or flow back along the shaft of the needle
into the arachnoidal space. This may account for why
clinically GBM metastasis rarely happen, but most
human GBM tumor cell lines intrinsically possess meta-
static potential. Moreover, GBM models produced by
most cell lines without stromal component always failed
Figure 2 Orthotopic xenografts in brain of mice revealed by MRI. 
A + B: the border of the orthotopic graft of human glioblastoma (white 
lines) was vague (A), in contrast to the sharp and clear edge of ortho-
topic graft of human brain metastasis (B white arrow). Post-Gd-DTPA 
sagittal T1W sequences revealed a typical enhancement in both A and 
B; C:Post-Gd-DTPA sagittal T1w sequences image of clinical case with 
brain metastasis of human lung adenocarcinoma(white arrow). The 
image was very similar to B.
Figure 3 Brain of tumor-bearing mice observed by eyes and un-
der lower power lens. A-C: brain metastasis tissues was implanted in 
right caudate nucleus. Tumor had grown to the brain surface of right 
hemisphere. The boundary between tumor and normal tissues was 
very clear seen by eyes (A and B) or under microscope(C arrow). D-F: 
the transplantation position of glioma was right caudate nucleus too. 
There was no tumor can be seen on the surface but brain edema was 
apparent. Under microscope Tumor cells were seen extensively invad-
ing to adjacent brain tissues.
Figure 4 Transplantation tumor observed by HE staining. Tumor 
cells of brain metastasis (A and B) were small round, easy to see 
caryocinesia, rare to see multinucleated giant cell and did not form 
glandular cavity in somewhere (B). Boundary (white dash line) be-
tween tumor (left) and normal brain tissues (right) was very clear (A). 
There was no apparent boundary can be seen between glioma tumor 
and surrounding brain tissues (C and D) and tumor cells invaded like 
chicken wire. Tumor cells were fusifirm, star-like, triangle and so on. 
Abundant vessels shown in tumor tissues and the dndothelial cells 
were hyperplasy (D).Fei et al. Journal of Experimental & Clinical Cancer Research 2010, 29:84
http://www.jeccr.com/content/29/1/84
Page 6 of 8
to invade the contiguous brain, growing by rather expan-
sive than diffusely infiltrative pattern. Taken together,
from the take rate to the recapitulation potentials, animal
model via cell suspension injection of established cell
lines seems far from desirable.
Tumor implantation in solid piece is theoretically supe-
rior to cell suspension injection in the following aspects:
1) when the transplantation volume is same, solid piece
contains tumor cells almost 20 times more than cell sus-
pension does; 2) besides the tumor cells, the stroma was
implanted at the same time, which provides a microeco-
system that favorites the cell growth and the maintenance
of the biological features of original tumors. Tumor trans-
plantation in solid piece was firstly reported by Shapiro et
al [18], however, the success rate is unexpectedly low,
with an overall take rate of 16% for human grade II-IV
astrocytomas, and 24% for GBMs. Recently, Antunes et al
[10] significantly improved the take rate by indirect trans-
plantation of human glioblastoma; however, he also
observed extracranial extension and scalp soft tissue infil-
tration of the resulting tumors, which never happens clin-
ically. Considering the trauma to the mice, the
complicated procedures, and other problems, tumor frag-
m e n t  g r a f t i n g  v i a  c r a n i o t o m y  s t i l l  h a s  m u c h  r o o m  f o r
improvement.
Enlightened by the advantages of cell suspension injec-
tion and disadvantages of tumor fragment grafting, we
designed to implant tumor in solid piece through injec-
tion. It is a simple but ingenious modification which
resulted in the following advantages in our model when
compared with implantation via craniotomy: 1) being
minimally invasive as only a very small skull hole is
Figure 5 Markers expressed in xenografts of brain metastasis. A: stroma was stained deep blue with Alcian blue staining indicating mucus se-
creted by tumor cells was acid. B: immunochemistry of CEA in brain metastasis showed nearly all tumor cells highly expressed CEA compared to nor-
mal tissues. C: immunochemistry of EGFR in glioma indicated most tumor cells expressed EGFR.
Figure 6 CD133 expressed in both original tumors and the implanted tumors. Tumor sections were stained against human specific CD133 by 
common immunochemistry, rare cells were positive for CD133 both in original tumors (A) and transplantation tumors (B). It could also be seen that 
CD133 positive cells distributed at the border (red dash line) between tumor mass(bottom) and the adjacent brain parenchyma (top in C).Fei et al. Journal of Experimental & Clinical Cancer Research 2010, 29:84
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enough; 2) high efficiency due to the simplified manipu-
lation; 3) being highly homogeneous, especially in sur-
vival time as the volume of implantation could be strictly
controlled; 4) no extracranial extension of tumor mass,
which is sometimes though not frequently encountered
in cases of craniotomy; 5)more reasonable mean survival
times of 38 days for metastasis model and 24 days for
glioblastoma mutiforme model. In some GBM mouse
models via craniotomy [10], the mean survival time is as
long as one year, which is absolutely beyond the rational
ranges when the survival time of a patients with brain
metastasis or glioblastoma multiforme and the average
expectation life time of a tumor-spared mouse are taken
into consideration.
Operative mortality in preliminary experiment was
high to 16.7%, some died because of traumatic intracra-
nial hemorrhage during operation, and other died
because of encephaledema after operation. We do our
best to reduce the surgical trauma to a minimum and
make zero death rates in perioperative period, though
there was some operation-related mortality in the prelim-
inary experiments. These deaths were mainly due to trau-
matic intracranial hemorrhage and/or brain edema after
operation. To avoid these accidents, we took the follow-
ing measures: 1) 22# trochar was replaced by 24# trochar;
2) transplantation volume was reduced to 2 mm3; and 3)
the tumor tissues were pushed as smoothly as possible.
Take rate is not the only criterion in evaluation of an
orthotopic animal model, while how close a model can
replicate the original tumors is more essential. As brain
metastasis and primary glioblastioma are two biologically
different malignances in the central nervous system, we
selected them both as grafts in this study to assess this
novel method. When compared between the two models,
metastasis xenografts were evidently differentiated from
glioblastoma xenograft in many aspects, however, when
compared with their original malignances, both models
demonstrated unquestionable similarity in histological
structure features and growth patterns. Laurent et al. [10]
performed both heterotransplantation and orthotopic
transplantation of human glioblastoma, and concluded
that the organ-specific environment play a determining
role in growth and invasive properties. In the current
study, two different malignances were transplanted into
the same organ; however, the resulting tumors didn't
demonstrate the similar growth patterns. So, it is more
plausible and acceptable that it is the malignance itself
but not environment that plays a determining role in the
tumor growth patterns and other biological behaviors.
With the identification of brain tumor stem cells from
tumor mass or cell lines, it is reported that as rare as 102
CD133+ glioma cells could generate tumor mass, while as
much as 106 CD133- glioma cells failed to form tumor
mass after injected to the mouse brain. The fact that cell
suspension injection of most established cell lines often
yields well-circumscribed intracranial tumors which are
different from the original tumor, coupled with the com-
plicated procedure of cell suspension injection precludes
tumor stem cells as a desirable transplant [19-21]. In this
study, the immunohistochemistry with monoclone anti-
body against CD133 revealed that not only the original
tumors, but the resulting tumors were positively stained
for CD133. This result means the tumor tissues contained
brain tumor stem cells and functioned as a tumor stem
cell pool. It is reported that biological behaviors of tumor
stem cells are highly dependent on their microenviron-
ment [22,23], in another word, CD133 negative tumor
cells and stromal components also play an important role
in the potential of tumor stem cells to re-establish the
original tumor. Taken together, tumor stem cells, other
tumor cells and stromal components make a concerted
contribution to the growth of tumor mass in transplanta-
tion animal model.
Conclusions
In conclusion, orthotopic xenograft mouse model of met-
astatic lung cancer and glioblastoma was established suc-
cessfully by our specially designed trocar implantation
system and it makes the orthotopic transplantation of
brain tumor into nude mice simpler, easier but more effi-
cient. When a large amount of homogeneous animal
modes are required in experiments, especially in new
antitumor drug tests, this method of tumor tissue injec-
tion promises the capacity to meet the demands.
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